Augmentin Adult Dosages for Infections

Standard Dosing Regimens

For adults with mild-to-moderate infections, the American Academy of Otolaryngology-Head and Neck Surgery recommends 500 mg/125 mg three times daily or 875 mg/125 mg twice daily, with the 875 mg formulation being preferred for respiratory tract infections 1, 2
The standard dosing regimen of 500 mg amoxicillin/125 mg clavulanate three times daily provides adequate coverage for most mild-to-moderate infections, according to the Journal of Allergy and Clinical Immunology 1
The 875 mg amoxicillin/125 mg clavulanate twice daily dose is preferred for respiratory infections, including acute bacterial rhinosinusitis, community-acquired pneumonia, and acute exacerbations of chronic bronchitis, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 2

For acute bacterial rhinosinusitis, the American Academy of Otolaryngology-Head and Neck Surgery recommends 500-875 mg twice daily for 5-7 days 2
For community-acquired pneumonia, the Journal of Allergy and Clinical Immunology recommends 875 mg twice daily, with duration based on clinical response 1
For acute exacerbations of chronic bronchitis, the Journal of Allergy and Clinical Immunology recommends 500-875 mg twice daily for at least 7 days 1

The clavulanate component is fixed at 125 mg per dose in standard formulations, regardless of amoxicillin content, as noted by the Journal of Allergy and Clinical Immunology and the American Academy of Otolaryngology-Head and Neck Surgery 1, 2
If no improvement occurs after 72 hours on initial therapy, the American Academy of Otolaryngology-Head and Neck Surgery recommends switching to a respiratory fluoroquinolone or high-dose amoxicillin/clavulanate if not already used 2

In areas where 25-50% of S. pneumoniae strains show penicillin resistance, high-dose regimens overcome this resistance through increased drug exposure, according to the Journal of Allergy and Clinical Immunology 1
The clavulanate component remains essential for adequate coverage of H. influenzae and M. catarrhalis, which produce beta-lactamase, as noted by the Journal of Allergy and Clinical Immunology 1